---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069622"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:03:50.860187+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OS Therapies reports Q2 2024 net operating loss of $1.557M; IPO raises $6.4M post-quarter

## Summary
- Q2 2024 net operating loss $1.557M vs $2.505M in Q2 2023; EPS loss $0.26 on 5.991M shares.
- IPO on July 31, 2024 raised $6.4M gross with no warrants; all preferred shares and debt converted to equity.
- Post-IPO shares outstanding: 20.85M common shares, with 1.86M tradable; 18.99M under 6-month lockup.
- Lead program OST-HER2 Phase 2b osteosarcoma trial final results expected Q4 2024; interim data from 39/41 patients.
- Cash runway extended to mid-2025 based on IPO proceeds; company reports no debt post-IPO.

## SEC filing metadata
- accession: 0001213900-24-069622
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390024069622/0001213900-24-069622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390024069622/ea0211542-8k_ostherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069622
- JSON: https://secwatch.observer/filing/0001213900-24-069622.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.